Physician profile
Son Chau
NPI 1023006111
$21,783.15
in general payments reported to CMS, 2019-2025
26 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $4,352 · 2021: $2,143 · 2022: $170 · 2023: $309 · 2024: $1,753 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,600 · Food and Beverage: $499 · Education: $85.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,600.00 |
| Food and Beverage | $498.76 |
| Education | $85.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $19,357.35 | 2019-2025 | Vemlidy |
| Astrazeneca Pharmaceuticals Lp | $318.36 | 2019-2022 | |
| Astellas Pharma US INC | $224.47 | 2019-2023 | |
| Watermark Medical, INC. | $172.45 | 2020 | |
| Glaxosmithkline, LLC. | $172.01 | 2020-2021 | |
| Novo Nordisk INC | $169.36 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.80 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $113.94 | 2019-2021 | |
| Pfizer INC. | $107.78 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $93.11 | 2019-2020 | |
| Biotronik INC. | $92.35 | 2020 | |
| Abbvie INC. | $90.90 | 2019 | |
| Hoffmann-La Roche Limited | $86.25 | 2019 | |
| Silk Road Medical, INC. | $76.34 | 2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
| Lilly USA, LLC | $76.32 | 2019-2023 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $71.18 | 2019-2022 | |
| Amgen INC. | $68.66 | 2019-2024 | Evenity, Prolia |
| Allergan, INC. | $67.46 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.16 | 2019-2020 | |
| Amarin Pharma, INC. | $47.97 | 2019-2020 | |
| Genentech USA, INC. | $44.25 | 2019 | |
| Merck Sharp & Dohme LLC | $35.41 | 2019 | |
| Abbott Laboratories | $26.09 | 2022-2023 | Proclaim |
| Radius Health, INC. | $20.93 | 2020 | |
| Sanofi-Aventis U.S. LLC | $19.85 | 2019 | |
| Evoke Pharma, INC. | $16.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Son Chau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.